ICIs are increasingly used in the treatment of cancer, yet the median OS improvement is modest, and many ICIs have not been tested for OS benefit. OS is the outcome most meaningful for patients, and drug regulation should require better testing and reporting of these data.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- dna damage
- prognostic factors
- palliative care
- papillary thyroid
- peritoneal dialysis
- adverse drug
- electronic health record
- squamous cell carcinoma
- big data
- emergency department
- machine learning
- squamous cell
- young adults
- combination therapy